Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis?
2012 (English)In: Cells, ISSN 2073-4409, Vol. 13, no 48, 153-167 p.Article in journal (Refereed) Published
The aim of this prospective study was to investigate the diagnostic performance of Borrelia (Bb)-induced interferon (IFN)-γ secretion detected by ELISPOT modified to be feasible for clinical laboratories as a supplementary test to the laboratory diagnosis of Lyme neuroborreliosis (LNB) in an endemic setting. Between 2002 and 2004, patients with symptoms of suspected clinical LNB were included in a study conducted on the Åland islands in the Finnish archipelago, which is a hyper-endemic area for Lyme borreliosis (LB). Fourteen patients with confirmed LNB and 103 patients with non-LNB were included, and the numbers of spontaneous and Bb-induced IFN-γ-secreting cells were assayed by the ELISPOT test. The ELISPOT assay showed a weak diagnostic performance with a sensitivity of 36% and a specificity of 82%. The findings in this study show that this ELISPOT-assay modified to be feasible in clinical routine laboratories is not useful as a supplementary diagnostic tool in the laboratory diagnosis of patients with clinically suspected LNB.
Place, publisher, year, edition, pages
Basel, Switzerland: MDPI AG , 2012. Vol. 13, no 48, 153-167 p.
Borrelia burgdorferi; neuroborreliosis; ELISPOT; cerebrospinal fluid; diagnostic test; sensitivity; specificity
Other Clinical Medicine
IdentifiersURN: urn:nbn:se:liu:diva-80259DOI: 10.3390/cells1020153PubMedID: 24710421OAI: oai:DiVA.org:liu-80259DiVA: diva2:546329